Skip to main content
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. — Investor Relations & Filings

Ticker · SABS ISIN · US0891152086 US Manufacturing
Open in API
Filings indexed 398 across all filing types
Latest filing 2025-04-01 Director's Dealing
Country US United States of America
Listing US SABS

About SAB Biotherapeutics, Inc.

https://www.sab.bio/

SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a novel class of immunotherapies. The company's proprietary platform produces targeted, high-potency, fully human polyclonal antibodies without the need for human donors. This technology utilizes transgenic cattle to generate natural human antibodies in response to specific disease targets. The company's lead product candidate, SAB-142, is a disease-modifying immunotherapy being developed to delay the onset and progression of Type 1 Diabetes (T1D) by addressing the underlying autoimmune cause. SAB's development pipeline also includes programs targeting infectious diseases, such as severe influenza and antibiotic resistance.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-04-01 English
10-K
Annual Report FY 2024
2025-03-28 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-14 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive lease agreement and the creation of a direct financial obligation. It includes details about the lease terms and references the attached lease agreement as an exhibit. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an announcement of a material contract and financial obligation, which fits the category of Capital/Financing Update (CAP). The document length is 4199 characters, which is typical for an 8-K filing. Therefore, the best classification is CAP with high confidence.
2025-02-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 28, 2025. It announces the issuance of a press release and a presentation regarding topline Phase 1 clinical results for SAB-142. The document includes references to the press release and presentation as exhibits but does not contain detailed financial statements or substantive financial data itself. The document length is 3565 characters, which is relatively short and primarily serves as an announcement of events and attached materials. According to the 'Menu vs Meal' rule, this is an announcement of reports (press release and presentation) rather than the reports themselves. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-01-28 English
4
Director's Dealing
2024-12-31 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.